Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790979 | 1.00 | SCN9A (0.57) | SCN9AMAOBMAOASIGMAR1MAPT | |
| Hydrochloric Acid SCHEMBL5966887 | 0.98 | SCN9A (0.56) | SCN9AMAOBMAOASIGMAR1MAPT | |
| SCHEMBL7395238 | 0.93 | SCN9A (0.55) | SCN9AMAOBMAOAITGB1ITGA5 | |
| SCHEMBL7401755 | 0.93 | SCN9A (0.55) | SCN9AMAOBMAOAITGB1ITGA5 | |
| SCHEMBL7399338 | 0.93 | SCN9A (0.55) | SCN9AMAOBMAOAITGB1ITGA5 | |
| SCHEMBL7395231 | 0.93 | SCN9A (0.55) | SCN9AMAOBMAOAITGB1ITGA5 | |
| SCHEMBL3290662 | 0.93 | SCN9A (0.55) | SCN9AMAOBMAOAL3MBTL1ITGB1 | |
| SCHEMBL3289039 | 0.93 | SCN9A (0.55) | SCN9AMAOBMAOAL3MBTL1ITGB1 | |
| SCHEMBL7390817 | 0.89 | FFAR1 (0.54) | SCN9AMAOBMAOA | |
| SCHEMBL7390821 | 0.89 | FFAR1 (0.54) | SCN9AMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3535310-B1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | COCA COLA CO (US) | 2025-12-24 | — | — | EP | claimed |
| US-11708454-B2 | Acrolein scavenging in PTF and other 1,3-propanediol derived polymers | THE COCA-COLA COMPANY (US) | 2023-07-25 | — | — | US | claimed |
| US-20190330420-A1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | THE COCA-COLA COMPANY (US) | 2019-10-31 | — | — | US | claimed |
| EP-3535310-A1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | The Coca-Cola Company (US) | 2019-09-11 | — | — | EP | claimed |
| CN-109996830-A | Acrolein scavenger in PTF and other 1, 3-propanediol derived polymers | 可口可乐公司 | 2019-07-09 | — | — | CN | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| WO-1995021814-A1 | NOVEL DERIVATIVES OF TETRAMETHYLCYCLOPROPANE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-08-17 | — | — | WO | claimed |
| EP-3535310-B1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | COCA COLA CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-11708454-B2 | Acrolein scavenging in PTF and other 1,3-propanediol derived polymers | THE COCA-COLA COMPANY (US) | 2023-07-25 | — | — | US | disclosed |
| US-20190330420-A1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | THE COCA-COLA COMPANY (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3535310-A1 | ACROLEIN SCAVENGING IN PTF AND OTHER 1,3-PROPANEDIOL DERIVED POLYMERS | The Coca-Cola Company (US) | 2019-09-11 | — | — | EP | disclosed |
| CN-109996830-A | Acrolein scavenger in PTF and other 1, 3-propanediol derived polymers | 可口可乐公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-105722516-A | A method for treating infection, sepsis and injury | 低温药理KF有限公司 | 2016-06-29 | — | — | CN | disclosed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | disclosed |
| EP-1045830-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARM SPA (IT) | 2003-04-23 | — | — | EP | disclosed |
| US-6306903-B1 | ANALGESICS FOR ALLEVIATION OF CHRONIC AND NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-23 | — | — | US | disclosed |
| EP-1045830-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035125-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| WO-1995021814-A1 | NOVEL DERIVATIVES OF TETRAMETHYLCYCLOPROPANE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | SCN9A 3634/4885MAOB 2501/4885MAOA 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.